Trial Information

NSABP MA.32 Ancillary Study of Biobehavioral Mechanisms of Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride Versus Placebo on NCIC-CTG-MA.32

This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with your other therapy to keep your cancer from recurring. Health Canada has not approved the sale or use of Metformin to treat breast cancer, although they have approved its use in this clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its use in breast cancer is considered investigational.

Patient Inclusion Criteria:

Age ≥ 18 years
Patient must be eligible for randomization in the NCIC-CTG-MA.32 treatment trial for breast cancer
Patient must have completed primary breast radiotherapy at least two weeks prior to enrollment on NSABP-NCIC-CTG-MA.32.F and is not planning to receive radiotherapy after starting NCIC-CTG-MA.32
Hormone receptor status known

Patient Exclusion Criteria:

None of the following allowed:

Patient must not have started taking NCIC-CTG-MA.32 study therapy

Janeen V. Bazan, RN OCN BSN CCRP, Oncology Research Nurse Program Coordinator
Sherman Health
1425 North Randall Road
Elgin, IL 60123
Phone: 224-783-2907
Fax: 224-783-3071
Email: janeen.bazan@shermanhospital.org

View Map

Research Center Information: Sherman Health

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.